Evidence map›Paper›PMID 40165995›Full record

ArticleDrug design, development and therapy2025

Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP.

Larissa N Ernst, Simon J Jaag, Valentin R Wydra, Benedikt Masberg, Cornelius Knappe, Stefan Gerstenecker, Ricardo A M Serafim, Xiaojun Julia Liang, Nico J Seidler, Michael Lämmerhofer and 2 more

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Larissa N ErnstDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Laboratory for Molecular Design and Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0003-0014-4496
Simon J JaagDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0002-3847-774X
Valentin R WydraDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0009-0004-3295-0526
Benedikt MasbergDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0003-2041-4983
Cornelius KnappeDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0009-0009-4080-4410
Stefan GersteneckerDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0002-7658-9945
Ricardo A M SerafimDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0003-0614-1798
Xiaojun Julia LiangDepartment of Medicinal Chemistry, Eberhard Karls Universität Tübingen, Faculty of Medicine, Institute for Biomedical Engineering, Tübingen, 72076, Germany.
Nico J SeidlerDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0009-0007-4405-2397
Michael LämmerhoferDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0002-1318-0974
Matthias GehringerDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität, Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0003-0163-3419
Frank M BoecklerDepartment of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Laboratory for Molecular Design and Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences, Tübingen, 72076, Germany.ORCID 0000-0001-8738-6716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The ubiquitin-specific protease 7 (USP7), also known as herpes-associated ubiquitin-specific protease (HAUSP) is an interesting target due to its role in the tumor suppressor p53 pathway. In recent years targeted covalent inhibitors have gained significant importance in pharmaceutical research. Thus, we have investigated a small library of 129 ligands bearing different types of covalent reactive groups ("warheads") from various kinase drug discovery projects for their reactivity towards the catalytic cysteine of USP7, as well as their influence on its melting temperature. These compounds mainly encompassed α,β-unsaturated amides specifically acrylamides, S Methods: We analyzed an array of 129 electrophilic compounds which had been designed as covalent kinase inhibitors in a DSF-based (differential scanning fluorimetry) screen against USP7. The hits were evaluated for their ability to cause similar thermal shifts for a CYS-deficient USP7 control mutant (USP7asoc), where only the catalytic Cys223 was retained. Additionally, covalent binding was evaluated by intact protein mass spectrometry (MS). Results: The DSF screen revealed that, predominantly 18 of the 129 tested compounds decreased the melting temperature of USP7 and its mutant USP7asoc. For 8 of these, the hypothesized covalent binding mode was corroborated with native and mutant USP7 by intact protein MS. Nearly all identified hits have a covalent warhead that reacts via nucleophilic aromatic substitution (S Conclusion: The screening and evaluation of the kinase library revealed several initial hits of interest. Seven S

Indexed as

Protein Kinase InhibitorsUbiquitin-Specific Peptidase 7Dose-Response Relationship, DrugHumansMolecular StructureSmall Molecule LibrariesStructure-Activity RelationshipProtein Kinase InhibitorsSmall Molecule LibrariesUbiquitin-Specific Peptidase 7USP7 protein, humancovalent cysteine modificationdifferential scanning fluorimetry (DSF)intact protein mass spectrometrynucleophilic aromatic substitution (SNAr)repurposing of kinase inhibitors

Identifiers

PMID40165995
PMCPMC11955496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.